Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia

ConclusionPopulation targeting using mutation testing forTP53 andIGHV when performed with del(17p) testing specifically in the context of frontline ibrutinib choice does not make a cost-ineffective treatment into a cost-effective treatment.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research